Ethics experts call for more thoughtful optimization of drug development process
(Medical Xpress)—McGill University post-doctoral fellow Spencer Phillips Hey and Prof. Jonathan Kimmelman, Biomedical Ethics, Social Studies of Medicine, Faculty of Medicine argue that some clinical trials of new drugs ...
Medications
May 09, 2013 |
not rated yet |
0
Healing hormone provides hope for brain injury
If Don Stein were the kind of man who listened to what others said, he would have shut down his lab years ago. The Emory neuroscientist spent more than two decades investigating progesterone as a treatment ...
Medical research
Apr 24, 2013 |
4.3 / 5 (4) |
0
New drug might help treat irritable bowel syndrome
(HealthDay)—A new drug significantly reduces the abdominal pain and constipation characteristic of certain types of irritable bowel syndrome, according to two new studies.
Diseases, Conditions, Syndromes
Sep 18, 2012 |
not rated yet |
0
|
Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer ...
Cancer
Sep 17, 2012 |
not rated yet |
0
Seasonal changes may influence the efficacy of vaccination against diabetes
The development of a medicine for patients with type 1 diabetes mellitus, based on autoantigen GAD65, received a setback following crucial clinical phase 3 trials that failed to show significant effects. One possible explanation ...
Diabetes
Feb 01, 2012 |
5 / 5 (1) |
0
Newly approved oral medication slows rheumatoid arthritis joint damage
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...
Arthritis & Rheumatism
Jan 24, 2013 |
5 / 5 (1) |
0
New medication shows promise as lipid-lowering therapy for rare cholesterol disorder
An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a ...
Medical research
Nov 02, 2012 |
4 / 5 (1) |
0
|
New Herceptin delivery method could vastly simplify breast cancer treatment
A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in hospital for some women undergoing breast cancer treatment, according to the results of a Phase 3 trial published ...
Cancer
Aug 08, 2012 |
not rated yet |
0
Limiting the problem of missing data urged for clinical trials
(HealthDay)—Data missing from clinical trials can undermine the credibility of those trials, and little attention has been focused on this issue until recently, experts say.
Medical research
Oct 04, 2012 |
not rated yet |
0
Vitreolytic ocriplasmin resolves vitreomacular traction
(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...
Diseases, Conditions, Syndromes
Aug 16, 2012 |
not rated yet |
0
Drug does not significantly reduce risk of death among patients with severe sepsis
Administration of the drug eritoran to patients with severe sepsis and septic shock failed to demonstrate a significant effect on reducing all-cause 28-day mortality or 1-year mortality, compared with placebo, according to ...
Diseases, Conditions, Syndromes
Mar 19, 2013 |
not rated yet |
0
For advanced prostate cancer, new drug slows disease
A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients ...
Cancer
Jun 02, 2012 |
not rated yet |
0
|
Teduglutide seems effective, safe for short bowel syndrome
(HealthDay)—For patients with short bowel syndrome with intestinal failure (SBS-IF), the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, ...
Diseases, Conditions, Syndromes
Dec 12, 2012 |
not rated yet |
0
Dual HER2 blockade significantly extends progression-free survival
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who ...
Cancer
Dec 08, 2011 |
not rated yet |
0
